Practices and opinions of specialized palliative care physicians regarding early palliative care in oncology.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 04 03 2019
accepted: 14 05 2019
pubmed: 6 6 2019
medline: 28 3 2020
entrez: 6 6 2019
Statut: ppublish

Résumé

To describe the practices and opinions of specialized palliative care (SPC) physicians regarding early palliative care for patients with cancer, determine characteristics associated with receiving early referrals; and solicit opinions regarding renaming the specialty "supportive care." The survey was distributed by mail and e-mail to physicians who had previously self-identified as providing palliative care. SPC physicians were defined as receiving palliative care referrals from other physicians and not providing palliative care only for their own patients. The response rate was 71% (531/746), of whom 257 (48.4%) practiced SPC. Of these SPC physicians, 84% provided mainly cancer care; > 90% supported early palliative care referral in oncology and had referral criteria facilitating this, but only 20% received early referrals (> 6-month prognosis). There was ambivalence regarding caring for patients with full resuscitation status and responsibility for managing cancer treatment-related complications. SPC physicians receiving early referrals were more likely to be female (p = 0.02) and have a postgraduate degree (p = 0.02), and less likely to provide mainly cancer care (p = 0.03) and to agree that patients should stop chemotherapy before referral (p = 0.009). Although 60% agreed that patients perceive the term "palliative care" negatively and 39% believed a name change to supportive care would encourage early referral, only 21% supported renaming the specialty. Although most SPC physicians supported early palliative care in oncology, the timing of referrals was often late, and was associated with characteristics of SPC physicians. Few SPC physicians supported renaming palliative care.

Identifiants

pubmed: 31165335
doi: 10.1007/s00520-019-04876-0
pii: 10.1007/s00520-019-04876-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

877-885

Subventions

Organisme : Canadian Cancer Society
ID : William E. Rawls prize
Organisme : Canadian Cancer Society Research Institute
ID : 700862
Organisme : CIHR
ID : 152996
Pays : Canada

Références

J Clin Oncol. 2015 Jul 10;33(20):2314-7
pubmed: 25918292
Palliat Support Care. 2013 Oct;11(5):397-404
pubmed: 23302500
J Natl Compr Canc Netw. 2013 Mar;11 Suppl 1:S11-6
pubmed: 23520181
Ann Oncol. 2015 Sep;26(9):1953-9
pubmed: 26088196
Eur J Cancer. 2016 Sep;65:61-8
pubmed: 27472648
J Palliat Med. 2006 Oct;9(5):1128-36
pubmed: 17040151
Palliat Med. 2009 Dec;23(8):698-707
pubmed: 19825895
J Clin Oncol. 2017 Jan;35(1):96-112
pubmed: 28034065
Ann Oncol. 2012 Feb;23(2):382-7
pubmed: 21804051
Support Care Cancer. 2013 Dec;21(12):3411-9
pubmed: 23942596
Lancet. 2014 May 17;383(9930):1721-30
pubmed: 24559581
J Clin Oncol. 2012 Dec 10;30(35):4380-6
pubmed: 23109708
J Oncol Pract. 2014 Mar;10(2):e37-44
pubmed: 24301842
BMJ. 2017 Jul 4;357:j2925
pubmed: 28676557
JAMA. 2009 Aug 19;302(7):741-9
pubmed: 19690306
BMC Palliat Care. 2014 Dec 16;13(1):59
pubmed: 25550683
Support Care Cancer. 2011 Mar;19(3):343-51
pubmed: 20157747
Ann Oncol. 2010 Feb;21(2):362-9
pubmed: 19654197
JAMA. 2016 Nov 22;316(20):2104-2114
pubmed: 27893131
Lancet Oncol. 2018 Nov;19(11):e588-e653
pubmed: 30344075
Lancet Oncol. 2018 Mar;19(3):394-404
pubmed: 29402701
Am J Prev Med. 2001 Jan;20(1):61-7
pubmed: 11137777
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
Support Care Cancer. 2008 Mar;16(3):217-22
pubmed: 17318594
Oncologist. 2011;16(1):105-11
pubmed: 21212438
Cancer. 2009 May 1;115(9):2013-21
pubmed: 19235253
CMAJ. 2016 Jul 12;188(10):E217-E227
pubmed: 27091801
Palliat Med. 2008 Jan;22(1):51-7
pubmed: 18216077

Auteurs

Anna Sorensen (A)

Department of Supportive Care, Princess Margaret Cancer Centre, 610 University Ave., 16-712, Toronto, Ontario, M5G 2M9, Canada.

Kirsten Wentlandt (K)

Department of Supportive Care, Princess Margaret Cancer Centre, 610 University Ave., 16-712, Toronto, Ontario, M5G 2M9, Canada.
Department of Family and Community Medicine, University of Toronto, Toronto, Canada.

Lisa W Le (LW)

Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.

Nadia Swami (N)

Department of Supportive Care, Princess Margaret Cancer Centre, 610 University Ave., 16-712, Toronto, Ontario, M5G 2M9, Canada.

Breffni Hannon (B)

Department of Supportive Care, Princess Margaret Cancer Centre, 610 University Ave., 16-712, Toronto, Ontario, M5G 2M9, Canada.
Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, Canada.

Gary Rodin (G)

Department of Supportive Care, Princess Margaret Cancer Centre, 610 University Ave., 16-712, Toronto, Ontario, M5G 2M9, Canada.
Princess Margaret Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Department of Psychiatry, University of Toronto, Toronto, Canada.

Monika K Krzyzanowska (MK)

Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, Canada.
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.

Camilla Zimmermann (C)

Department of Supportive Care, Princess Margaret Cancer Centre, 610 University Ave., 16-712, Toronto, Ontario, M5G 2M9, Canada. camilla.zimmermann@uhn.ca.
Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, Canada. camilla.zimmermann@uhn.ca.
Princess Margaret Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. camilla.zimmermann@uhn.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH